Analyst Price Targets — ADMA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 11:23 am | — | Mizuho Securities | $17.00 | $8.87 | TheFly | Adma Biologics price target lowered to $17 from $20 at Mizuho |
| June 10, 2026 11:25 am | Ryan Deschner | Raymond James | $21.00 | $8.12 | TheFly | Adma Biologics resumed with an Outperform at Raymond James |
| May 7, 2026 10:40 am | Gary Nachman | Canaccord Genuity | $18.00 | $10.08 | TheFly | Adma Biologics price target lowered to $18 from $21 at Canaccord |
| April 20, 2026 8:20 pm | — | Canaccord Genuity | $21.00 | $10.88 | TheFly | Adma Biologics initiated with a Buy at Canaccord |
| April 13, 2026 2:35 pm | Anthony Petrone | Mizuho Securities | $24.00 | $10.33 | TheFly | Adma Biologics price target lowered to $24 from $30 at Mizuho |
| October 14, 2024 6:58 am | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $17.15 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on ADMA Biologics (ADMA) |
| June 20, 2024 6:47 am | Anthony Petrone | Mizuho Securities | $14.00 | $10.62 | StreetInsider | ADMA Biologics (ADMA) PT Raised to $14 at Mizuho |
| January 3, 2023 6:14 am | — | H.C. Wainwright | $4.50 | $3.88 | Benzinga | HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $4.5 |
| November 10, 2022 10:24 am | — | Mizuho Securities | $6.00 | $3.05 | Benzinga | Mizuho Maintains Buy on ADMA Biologics, Raises Price Target to $6 |
| July 25, 2022 6:44 am | — | H.C. Wainwright | $4.00 | $2.17 | Benzinga | HC Wainwright & Co. Maintains Buy on ADMA Biologics, Lowers Price Target to $4 |
Latest News for ADMA
New York, New York--(Newsfile Corp. - July 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ADMA…
ADMA Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick and Foti, L
NEW YORK, July 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased ADMA Biologics securities…
/PRNewswire/ -- Kahn Swick and Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ADMA.
U.S. House Trading
No House trades found for ADMA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.